The bill would establish a nonprofit Foundation for Enabling Biotechnology Innovation under the National Science Foundation. Its mission is to accelerate commercialization of U.S. biotechnology products by boosting cross‑sector collaboration, coordinating with federal agencies, and expanding education and outreach.
It would fund partnerships, stakeholder convenings, market access efforts, and research on commercialization processes, while ensuring the foundation operates independently of government regulation and oversight.
At a Glance
What It Does
Establishes a nonprofit Foundation under NSF to accelerate biotechnology commercialization. It would fund partnerships, stakeholder engagement, education programs, and cross‑agency collaboration, while evaluating regulation of future biotech products. The Foundation would not regulate products itself.
Who It Affects
Biotech firms, universities, research institutions, industry associations, and non‑profits involved in biotechnology commercialization; federal agencies that participate in cross‑sector efforts; and organizations that may partner or receive Foundation funding.
Why It Matters
Sets up a formal, multi‑stakeholder mechanism to translate research into products, potentially shortening development timelines, aligning standards, and reducing friction between innovation and regulation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Foundation for Enabling Biotechnology Innovation is designed to speed the transfer of biotechnology research into commercial products in the United States. It is established by the NSF and governed by a Board of Directors drawn from academia, industry, and non-profit sectors, with ex officio participation from key federal agencies but no voting power for those agencies.
The Foundation’s activities include promoting public-private partnerships, convening stakeholders for horizon scanning and regulatory foresight, and supporting education, fellowships, and market access initiatives. It may also fund studies, support discrete federal projects, and engage in international diplomacy to align norms and standards in biotechnology commercialization.
The Foundation is not a federal agency and will not regulate biotechnology products. It can receive gifts and grants, but only under terms set by its bylaws, and it must maintain transparency through annual reports and donor disclosures.
The NSF will provide a baseline $4 million per year in funding, and the Foundation must work toward financial self‑sustainability within five years, with the goal of maintaining complementarity with existing federal programs. Finally, the bill imposes governance and integrity provisions designed to prevent conflicts of interest and protect the integrity of both the Foundation and related federal programs.
The Five Things You Need to Know
The Foundation is established under the NSF and named the Foundation for Enabling Biotechnology Innovation.
The Foundation’s mission is to accelerate biotech commercialization by fostering cross‑sector collaboration and improving regulatory horizon scanning.
A Board with at least 5 voting members will govern the Foundation; ex officio federal members are nonvoting.
NSF must transfer not less than $4 million per year to the Foundation, starting in 2026.
The Foundation must publish annual reports, undergo audits, and maintain rigorous conflict‑of‑interest and donor‑disclosure standards.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Foundation establishment, mission, and activities
The bill establishes the Foundation for Enabling Biotechnology Innovation as a nonprofit entity within the federal framework, to be known by the specified name. Its mission is to accelerate commercialization of biotechnology products in the United States by strengthening cross‑sector collaboration, supporting federal‑agency engagement, and promoting public outreach. The Foundation may pursue activities including promoting public‑private partnerships, convening stakeholders for horizon scanning and regulatory foresight, fostering collaboration among federal agencies and academia, conducting outreach and education, facilitating market access and international engagement, funding studies on market acceptance and regulatory processes, and supporting fellowship and education programs to build commercialization capacity.
Limitation: non‑agency and non‑regulatory role
The Foundation is explicitly not an agency or instrumentality of the Federal Government and it may not regulate biotechnology products or any other products. This provision preserves the regulatory authority and program responsibilities of existing federal agencies while enabling the Foundation to focus on facilitation, coordination, and funding activities designed to accelerate commercialization.
Support and fundraising authority
The Foundation may receive, administer, solicit, accept, and use funds from gifts, bequests, grants, or other forms of support. Donor restrictions and designations are to be governed by the Foundation’s bylaws, with safeguards to ensure appropriate use of funds and to prevent inappropriate designations that could undermine mission integrity.
Tax-exempt status
The Foundation is directed to obtain and maintain Section 501(c)(3) tax‑exempt status. The Board must take all necessary steps to ensure compliance with tax‑exemption rules and maintain transparency about financial activities and donor restrictions.
Board of Directors: composition and appointment
The Foundation will be governed by a Board of Directors. Voting members must come from a broad cross‑section of sectors, regions, and communities and possess experience to advance biotechnology commercialization. No federal employee may serve as a voting member. Initial voting members will be drawn from a list developed with the National Academies and appointed within 180 days of enactment; ex officio nonvoting members will include senior officials from DoD, Agriculture, HHS, and EPA, among others, as determined by the Board.
Administration: CEO and planning
The Foundation will appoint a Chief Executive Officer responsible for executing the Foundation’s activities, hiring, managing funds, and entering into contracts. Not later than one year after CEO appointment, the Foundation must submit a strategic plan outlining financial goals, 5‑year objectives, transparency measures, and plans to ensure complementarity with federal biotech programs, along with annual reporting requirements and a 10‑year financing roadmap.
Integrity, governance, and citizenship
The bill requires the Foundation to implement standards of conduct, disclosure, and conflict‑of‑interest policies. Officers, employees, and Board members must meet citizenship requirements designed to mitigate foreign influence. The governance framework includes recusal procedures for potential conflicts and oversight to protect the integrity of Foundation activities and any federal related programs.
Appropriations and transfers
Appropriations are authorized for the NSF to provide $4 million per fiscal year for the Foundation’s operations, and the NSF Director shall transfer not less than $4 million each year to the Foundation. The Foundation must maintain separate fund accounts from other NSF activities.
Definitions
Key terms defined include ‘Board,’ ‘Foundation,’ ‘foreign country of concern,’ ‘foreign entity of concern,’ ‘institution of higher education,’ and ‘relative,’ with cross‑references to relevant U.S. law definitions to ensure consistent interpretation and risk management.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Biotechnology companies and startups gain access to structured pathways for market entry, partnerships, and potential funding channels that can reduce commercialization risk.
- Universities and research institutions obtain formal channels for collaboration and talent development via fellowships and capstone projects.
- Federal agencies involved in biotech policy and regulation gain a structured forum for coordination, reducing duplication and aligning programs.
- Industry associations and nonprofit organizations can participate in horizon scanning, standard setting, and education initiatives that support a healthier innovation ecosystem.
- Public stakeholders may benefit from accelerated development of biotech products and clearer norms and standards through cross‑agency dialogue.
Who Bears the Cost
- Private donors and philanthropic partners may face increased reporting expectations and governance requirements to ensure funds are used per bylaws.
- The Foundation will incur administrative and compliance costs associated with audits, reporting, and donor disclosures.
- Federal agencies may experience increased collaboration overhead and need to align with Foundation activities, including data sharing and monitoring.
- NSF and infrastructure costs rise due to ongoing funding and oversight obligations to sustain the Foundation and its programs.
- Taxpayer resources could be affected indirectly through appropriations to the NSF and related oversight obligations, though the bill aims to create efficiencies in commercialization.
Key Issues
The Core Tension
The central tension is whether a semi‑independent Foundation, funded largely through private and interagency resources, can credibly accelerate biotechnology commercialization while maintaining robust public accountability, rigorous governance, and alignment with existing federal programs.
The bill creates a new, hybrid entity intended to bridge government and private sectors in biotechnology commercialization. The tension here is between enabling rapid private-sector activity and preserving public accountability and scientific independence.
Relying on private funding and cross‑sector governance raises questions about oversight, donor influence, and how to prevent conflicts of interest from skewing research priorities or policy alignment. Furthermore, establishing a separate Foundation funded through annual transfers may duplicate or blur lines of authority with existing federal programs, requiring careful coordination to avoid fragmentation of federal biotech policy and ensure that the Foundation’s activities complement rather than compete with NSF and other agencies.
A practical challenge is sustainability: while the plan anticipates self‑sufficiency within five years, it hinges on steady non‑federal funding streams and the Foundation’s ability to attract dollars without compromising integrity or public trust. The governance provisions—particularly the mix of voting and ex officio nonvoting membership, the limits on public officials serving as voting members, and the disclosure and conflict‑of‑interest requirements—are designed to mitigate risk, but the real test will be ensuring transparent decision‑making and effective alignment with national biotech goals without creating opaque channels for private interests to influence critical research and standard‑setting.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.